Category

Insights
Medlior Publications

Medlior Publications

Explore a list of all of Medlior's recent publications including recent Medlior evidence generation publications and recent Medlior RWE publications. Cowling T, Loshak H. An Overview of Liquid Biopsy for Screening and Early Detection of Cancer. Ottawa: CADTH; 2019...

Case Study: Atherosclerotic Cardiovascular Disease

Case Study: Atherosclerotic Cardiovascular Disease

Medlior’s RWE study examining the treatment landscape and clinical outcomes for patients with atherosclerotic cardiovascular disease in Alberta Introduction Medlior Health Outcomes Research Ltd. was engaged by Amgen Inc., one of the world’s leading biopharmaceutical...

EAHAD 2020: Haemophilia-A SLR Project

EAHAD 2020: Haemophilia-A SLR Project

Haemophilia-A (HA) is a congenital x‐linked bleeding disorder caused by a deficiency of blood coagulation factor VIII (FVIII), occurring in approximately one in every 5000 male live births. HA is currently without a cure and therefore requires life-long monitoring and treatment of potentially life‐threatening bleeding events. Existing treatments for the management of this disorder include the use of plasma‐derived factor concentrates, recombinant factor concentrates, and more recently, monoclonal antibodies (e.g. emicizumab).

DLBCL Environmental Scan

DLBCL Environmental Scan

Understanding and identifying the unmet need of aggressive B-cell lymphomas is critical for positioning new therapies Aggressive B-cell lymphomas are a subset of non-Hodgkin’s lymphoma (NHL) that encompass a number of neoplasms that include both precursor lymphoid...

Case Study: Multiple Myeloma

Case Study: Multiple Myeloma

Medlior Health Outcomes Research was engaged by Celgene Canada (now a subsidiary of Bristol-Myers Squibb Company) to examine the treatment landscape for patients with multiple myeloma (MM) and the effects of lenalidomide (REVLMID®) as an immunomodulatory imide drug for both newly-diagnosed MM patients and relapsed/refractory MM patients. 

Lipid-lowering Therapy Patterns and Low-density Lipoprotein-Cholesterol Management Among Patients with Acute Myocardial Infarction in Alberta, Canada

Lipid-lowering Therapy Patterns and Low-density Lipoprotein-Cholesterol Management Among Patients with Acute Myocardial Infarction in Alberta, Canada

Medlior’s presentation focuses on a real-world evidence study sponsored by Amgen Inc. examining the management of patients with an acute myocardial infarction (AMI) in Alberta, Canada. AMI is a leader in disease burden and death worldwide. In order to combat AMI, modifiable factors that lower cholesterol, specifically low-density lipoprotein-cholesterol (LDL-C) are needed. Therapies designed to lower LDL-C, such as statins, also called lipid lowering therapies (LLT), are therefore important to understand the patterns of use and to what extent LDL-C is lowered. Medlior’s study utilized health system data to explore the patterns of LLT and the management of LDL-C levels in patients who experienced AMI.

Coronavirus background and key questions

Coronavirus background and key questions

As the COVID-19 virus spreads, world governments implement control strategies This article is about an emerging and rapidly evolving public health crisis. Case and death counts change daily. If you’re interested in learning the very latest information please consult...